Virax Biolabs Group Limit... (VRAX)
Virax Biolabs Statistics
Share Statistics
Virax Biolabs has 4.34M shares outstanding. The number of shares has increased by 83.83% in one year.
| Shares Outstanding | 4.34M |
| Shares Change (YoY) | 83.83% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 3.14% |
| Shares Floating | 4.05M |
| Failed to Deliver (FTD) Shares | 61 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 446.54K, so 10.28% of the outstanding shares have been sold short.
| Short Interest | 446.54K |
| Short % of Shares Out | 10.28% |
| Short % of Float | 11.01% |
| Short Ratio (days to cover) | 0.11 |
Valuation Ratios
The PE ratio is -0.22 and the forward PE ratio is -1.08. Virax Biolabs's PEG ratio is 0.01.
| PE Ratio | -0.22 |
| Forward PE | -1.08 |
| PS Ratio | 9.43 |
| Forward PS | 0.4 |
| PB Ratio | 0.27 |
| P/FCF Ratio | -0.2 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Virax Biolabs.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 25.94, with a Debt / Equity ratio of 0.04.
| Current Ratio | 25.94 |
| Quick Ratio | 25.58 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.03 |
| Interest Coverage | -241.7 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $9.2K |
| Profits Per Employee | $-396.09K |
| Employee Count | 17 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 1.75 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 31.76% in the last 52 weeks. The beta is 1.59, so Virax Biolabs's price volatility has been higher than the market average.
| Beta | 1.59 |
| 52-Week Price Change | 31.76% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 1.96 |
| Relative Strength Index (RSI) | 34.62 |
| Average Volume (20 Days) | 271.03K |
Income Statement
In the last 12 months, Virax Biolabs had revenue of 156.42K and earned -6.73M in profits. Earnings per share was -3.36.
| Revenue | 156.42K |
| Gross Profit | 50.59K |
| Operating Income | -6.5M |
| Net Income | -6.73M |
| EBITDA | -6.61M |
| EBIT | -6.71M |
| Earnings Per Share (EPS) | -3.36 |
Balance Sheet
The company has 3.59M in cash and 224.3K in debt, giving a net cash position of 3.36M.
| Cash & Cash Equivalents | 3.59M |
| Total Debt | 224.3K |
| Net Cash | 3.36M |
| Retained Earnings | -18.53M |
| Total Assets | 9.44M |
| Working Capital | 7.34M |
Cash Flow
In the last 12 months, operating cash flow was -6.25M and capital expenditures -1.16M, giving a free cash flow of -7.41M.
| Operating Cash Flow | -6.25M |
| Capital Expenditures | -1.16M |
| Free Cash Flow | -7.41M |
| FCF Per Share | -3.69 |
Margins
Gross margin is 32.34%, with operating and profit margins of -4153.25% and -4304.81%.
| Gross Margin | 32.34% |
| Operating Margin | -4153.25% |
| Pretax Margin | -4308.38% |
| Profit Margin | -4304.81% |
| EBITDA Margin | -4225.28% |
| EBIT Margin | -4153.25% |
| FCF Margin | -4738.21% |
Dividends & Yields
VRAX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for VRAX is $3, which is 167.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 167.9% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Dec 18, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Dec 18, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -4.08 |
| Piotroski F-Score | 3 |